214 related articles for article (PubMed ID: 38300808)
1. GLP-1 and PYY for the treatment of obesity: a pilot study on the use of agonists and antagonists in diet-induced rats.
Oertel M; Ziegler CG; Kohlhaas M; Nickel A; Kloock S; Maack C; Sequeira V; Fassnacht M; Dischinger U
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38300808
[TBL] [Abstract][Full Text] [Related]
2. Effects of NPY-2 Receptor Antagonists, Semaglutide, PYY
Kloock S; Haerting N; Herzog G; Oertel M; Geiger N; Geier A; Sequeira V; Nickel A; Kohlhaas M; Fassnacht M; Dischinger U
Nutrients; 2024 Mar; 16(6):. PubMed ID: 38542814
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 and PYY
Dischinger U; Corteville C; Otto C; Fassnacht M; Seyfried F; Hankir MK
Surg Obes Relat Dis; 2019 Sep; 15(9):1483-1492. PubMed ID: 31548004
[TBL] [Abstract][Full Text] [Related]
4. Engineering a potent and long-acting GLP-1/Y
Xu J; Wang S; Wu H; Chen D; Han J; Lin Q
Peptides; 2023 Nov; 169():171073. PubMed ID: 37536423
[TBL] [Abstract][Full Text] [Related]
5. Toward a Medical Gastric Bypass: Chronic Feeding Studies With Liraglutide + PYY
Dischinger U; Hasinger J; Königsrainer M; Corteville C; Otto C; Fassnacht M; Hankir M; Seyfried FJD
Front Endocrinol (Lausanne); 2020; 11():598843. PubMed ID: 33551994
[TBL] [Abstract][Full Text] [Related]
6. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
Thorsø Larsen A; Karsdal MA; Henriksen K
Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
[TBL] [Abstract][Full Text] [Related]
7. Modified Peptide YY Molecule Attenuates the Activity of NPY/AgRP Neurons and Reduces Food Intake in Male Mice.
Jones ES; Nunn N; Chambers AP; Østergaard S; Wulff BS; Luckman SM
Endocrinology; 2019 Nov; 160(11):2737-2747. PubMed ID: 31074796
[TBL] [Abstract][Full Text] [Related]
8. The effect of peptide tyrosine tyrosine (PYY3-36), a selective Y2 receptor agonist on streptozotocin-induced diabetes in albino rats.
Abdel-Hamid HA; Abdalla MMI; Zenhom NM; Ahmed RF
Endocr Regul; 2019 Jan; 53(1):26-33. PubMed ID: 31517617
[TBL] [Abstract][Full Text] [Related]
9. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A
Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383
[TBL] [Abstract][Full Text] [Related]
10. Time and metabolic state-dependent effects of GLP-1R agonists on NPY/AgRP and POMC neuronal activity in vivo.
Dong Y; Carty J; Goldstein N; He Z; Hwang E; Chau D; Wallace B; Kabahizi A; Lieu L; Peng Y; Gao Y; Hu L; Betley JN; Williams KW
Mol Metab; 2021 Dec; 54():101352. PubMed ID: 34626854
[TBL] [Abstract][Full Text] [Related]
11. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Glucagon-Like Peptide-1 Receptor Agonists Suppress Voluntary Alcohol Intake in Male Wistar Rats.
Marty VN; Farokhnia M; Munier JJ; Mulpuri Y; Leggio L; Spigelman I
Front Neurosci; 2020; 14():599646. PubMed ID: 33424537
[TBL] [Abstract][Full Text] [Related]
13. Regionally-selective down-regulation of NPY receptor subtypes in the obese Zucker rat. Relationship to the Y5 'feeding' receptor.
Widdowson PS
Brain Res; 1997 May; 758(1-2):17-25. PubMed ID: 9203528
[TBL] [Abstract][Full Text] [Related]
14. NPY Y2 receptor agonist PYY(3-36) inhibits diarrhea by reducing intestinal fluid secretion and slowing colonic transit in mice.
Moriya R; Shirakura T; Hirose H; Kanno T; Suzuki J; Kanatani A
Peptides; 2010 Apr; 31(4):671-5. PubMed ID: 19925840
[TBL] [Abstract][Full Text] [Related]
15. GLP-1 receptor agonism and GIP receptor antagonism induce substantial alterations in enteroendocrine and islet cell populations in obese high fat fed mice.
Sridhar A; Khan D; Flatt PR; Moffett CR; Irwin N
Peptides; 2023 Nov; 169():171093. PubMed ID: 37660881
[TBL] [Abstract][Full Text] [Related]
16. Decreased plasma peptide YY accompanied by elevated peptide YY and Y2 receptor binding densities in the medulla oblongata of diet-induced obese mice.
Rahardjo GL; Huang XF; Tan YY; Deng C
Endocrinology; 2007 Oct; 148(10):4704-10. PubMed ID: 17615145
[TBL] [Abstract][Full Text] [Related]
17. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
18. Peripheral activation of the Y2-receptor promotes secretion of GLP-1 and improves glucose tolerance.
Chandarana K; Gelegen C; Irvine EE; Choudhury AI; Amouyal C; Andreelli F; Withers DJ; Batterham RL
Mol Metab; 2013; 2(3):142-52. PubMed ID: 24049729
[TBL] [Abstract][Full Text] [Related]
19. Peptide-YY
Boland BB; Laker RC; O'Brien S; Sitaula S; Sermadiras I; Nielsen JC; Barkholt P; Roostalu U; Hecksher-Sørensen J; Sejthen SR; Thorbek DD; Suckow A; Burmeister N; Oldham S; Will S; Howard VG; Gill BM; Newton P; Naylor J; Hornigold DC; Austin J; Lantier L; McGuinness OP; Trevaskis JL; Grimsby JS; Rhodes CJ
Mol Metab; 2022 Jan; 55():101392. PubMed ID: 34781035
[TBL] [Abstract][Full Text] [Related]
20. Peptide Tyrosine-Tyrosine Triggers GLP-2-Mediated Intestinal Hypertrophy After Roux-en-Y Gastric Bypass.
Pérez-Arana GM; Díaz-Gómez A; Camacho-Ramírez A; Ribelles-García A; Almorza-Gomar D; Gracia-Romero M; Prada-Oliveira JA
Obes Surg; 2022 Dec; 32(12):4023-4032. PubMed ID: 36301409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]